

Market Outlook

The Nifty 50 closed at 25,879, witnessing a muted session. On the daily chart, the index faced selling pressure near the key hurdle of 26,000 and ended the day flat. In the derivatives segment, fresh Call OI build-up was observed at the 26,000 strike, marking it as a crucial level to watch for any further upside potential. On the downside, some covering was seen in ATM Put options, while significant Put OI build-up emerged at the 25,500 strike, indicating that a sustained move below the 26,000 level could trigger a corrective decline towards 25,500 in the coming sessions.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	25879.15	0.01
SENSEX	84478.67	0.01
BANKNIFTY	58381.95	0.18
INDIA VIX	12.16	0.43

FII STATISTICS


FII F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	453.62	-2.04%
Index Options	8149.44	13.28%
Stock Futures	924.08	-0.50%
Stock Options	-422.90	5.66%

FII & DII Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	-383.68	-8685	-118905
DII	3091.87	32890	475340

FII Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
ETERNAL	39982055	1.88	45.26
INFY	15342199	3.56	34.3
ICICIBANK	13863137	5.71	87.91
POWERGRID	8440110	-10.4	-23.54
HDFCBANK	8400766	-9.52	7.52
TMPV	7840657	-1.3	1.74
BAJFINANCE	6008139	-0.99	-23.6
SBIN	5037758	-1.21	26.28
NTPC	4686634	2.02	6.21
RELIANCE	4619589	0.7	-41.89


NIFTY

Nifty	25953.80
OI (In contracts)	234364
CHANGE IN OI (%)	-0.99
PRICE CHANGE (%)	-0.12
IMPLICATION	LONG UNWINDING

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
PGEL	561.75	5.99	8741600	11.35
MOTHERSON	109.49	2.89	181363500	10.21
NUVAMA	7406	0.25	326475	8.93
DELHIVERY	435.8	0.50	18419775	7.27
DIXON	15378	0.00	1911100	4.58


BANKNIFTY

Banknifty	58535.00
OI (In contracts)	49122
CHANGE IN OI (%)	-8.55
PRICE CHANGE (%)	0.02
IMPLICATION	SHORT COVERING

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
ALKEM	5744	-1.03	1800000	12.48
NBCC	108.79	-2.98	83232500	9.50
IRCTC	705.6	-1.38	15749125	6.24
ETERNAL	299.1	-3.58	286137875	5.87
TATASTEEL	176.84	-1.44	227683500	5.40

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
NATIONALUM	44475000	35208750	1.26
BPCL	19746050	16775650	1.18
PETRONET	15492600	13329000	1.16
KPITTECH	1798900	1595375	1.13
POWERINDIA	335900	298100	1.13
CANBK	117362250	106852500	1.1
SHRIRAMFIN	18336450	17115450	1.07
IOC	61546875	58612125	1.05
BIOCON	23902500	23595000	1.01
BHEL	47528250	47706750	1

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
GMRAIRPORT	43551900	132964425	0.33
ONGC	18265500	56031750	0.33
SHREECEM	57225	172750	0.33
NESTLEIND	1975500	5504000	0.36
360ONE	741500	1979500	0.37
DELHIVERY	10617775	28616325	0.37
KFINTECH	1739150	4700250	0.37
YESBANK	176368100	468956900	0.38
APOLLOHOSP	901125	2304125	0.39
KAYNES	866300	2223700	0.39

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2553	2617	2459	2395	2301
ADANIPTS	1527	1543	1503	1487	1463
APOLLOHOSP	7566	7600	7525	7491	7451
ASIANPAINT	2859	2948	2751	2662	2554
AXISBANK	1235	1244	1229	1221	1215
BAJAJ-AUTO	8952	9020	8882	8815	8745
BAJAJFINSV	2076	2108	2015	1983	1922
BAJFINANCE	1036	1055	1024	1005	994
BEL	430	434	426	422	419
BHARTIARTL	2096	2107	2079	2067	2050
CIPLA	1532	1540	1526	1518	1511
COALINDIA	390	392	387	386	383
DRREDDY	1242	1250	1230	1222	1210
EICHERMOT	6945	6997	6899	6847	6802
ETERNAL	314	317	311	307	304
GRASIM	2791	2811	2775	2755	2739
HCLTECH	1608	1617	1593	1584	1569
HDFCBANK	1000	1006	996	991	987
HDFCLIFE	792	800	779	771	758
HINDALCO	807	816	802	793	788
HINDUNILVR	2443	2453	2434	2425	2415
ICICIBANK	1368	1374	1365	1359	1355
INDIGO	5835	5869	5801	5767	5733
INFY	1542	1551	1531	1522	1511
ITC	410	411	408	407	406

SYMBOL	R1	R2	PP	S1	S2
JIOFIN	313	315	310	308	305
JSWSTEEL	1193	1201	1188	1180	1175
KOTAKBANK	2104	2113	2097	2088	2081
LT	3982	4001	3964	3945	3926
M&M	3785	3806	3766	3745	3726
MARUTI	15802	15862	15706	15646	15550
MAXHEALTH	1129	1153	1105	1082	1057
NESTLEIND	1293	1303	1279	1269	1256
NTPC	329	331	328	326	325
ONGC	257	259	254	252	249
POWERGRID	270	272	269	267	266
RELIANCE	1529	1540	1516	1505	1493
SBILIFE	2015	2028	2002	1990	1977
SBIN	963	967	960	956	953
SHRIRAMFIN	837	848	831	820	815
SUNPHARMA	1753	1767	1734	1720	1701
TATACONSUM	1170	1175	1164	1159	1152
TATASTEEL	182	184	180	178	176
TCS	3165	3191	3115	3089	3039
TECHM	1480	1497	1449	1432	1401
TITAN	3893	3924	3853	3821	3782
TMPV	409	414	406	401	398
TRENT	4439	4481	4371	4329	4261
ULTRACEMCO	12006	12046	11939	11899	11832
WIPRO	248	250	246	244	242

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com
<i>Vivek Chandra</i>	vivek.chandra@religare.com
<i>Himanshu Gupta</i>	himanshu.gupta1@religare.com
<i>Vishvajeet Singh</i>	vishvajeet.singh1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results